### Contraindications

**Varicella vaccines (WHO position paper)**

In immunocompromised persons, including patients with advanced HIV infection, varicella vaccination is currently contraindicated for fear of disseminated vaccine induced disease.

**Varicella vaccines (WHO position paper)**

Contraindications for varicella vaccination include a history of anaphylactic reactions to any component of the vaccine (including neomycin), pregnancy (due to theoretical risk to the fetus; pregnancy should be avoided for 4 weeks following vaccination), ongoing severe illness, and advanced immune disorders of any type.

Except for patients with acute lymphatic leukaemia in stable remission, ongoing treatment with systemic steroids (for adults >20 mg/day, for children >1mg/kg/day) is considered a contraindication for varicella vaccination. A history of congenital immune disorders in close family members is a relative contraindication.

**Varicella vaccines (WHO position paper)**

Recommendations on possible use of (varicella) vaccine for persons in certain states of immunodeficiency are beyond the scope of this article. Advice is provided by several expert panels such as the Advisory Committee on Immunization Practices (ACIP) in the United States.

### General

**Varicella vaccines (WHO position paper)**

Routine childhood immunization against varicella may be considered in countries where this disease is a relatively important public health and socioeconomic problem, where the vaccine is affordable, and where high (85%-90%) and sustained vaccine coverage can be achieved. (Childhood immunization with lower coverage could theoretically shift the epidemiology of the disease and increase the number of severe cases in older children and adults.)

**Varicella vaccines (WHO position paper)**

(Varicella) vaccine may be offered in any country to individual adolescents and adults without a history of varicella, in particular to those at increased risk of contracting or spreading the infection. This use in adolescents and adults entails no risk of an epidemiological shift, as childhood exposure to VZV remains unaffected.

---

WER 1998, vol. 73, 32, pp 241-248

page 246

WER 1998, vol. 73, 32, pp 241-248

page 246

WER 1998, vol. 73, 32, pp 241-248

page 248

WER 1998, vol. 73, 32, pp 241-248

page 241

WER 1998, vol. 73, 32, pp 241-248

page 241
Varicella vaccines (WHO position paper)

When given at separate sites and with separate syringes, simultaneous vaccination of varicella with other vaccines is as safe and immunogenic as when the vaccines are given at intervals of several weeks.

Varicella vaccines (WHO position paper)

From a logistic as well as an epidemiological point of view, the optimal age for varicella vaccination is 12-24 months.

In Japan and several other countries 1 dose of the (varicella) vaccine is considered sufficient, regardless of age. In the United States, 2 doses, 4-8 weeks apart, are recommended for adolescents and adults, in whom 78% were found to have seroconverted after the first, and 99% after the second dose of the vaccine. Children below 13 years receive only 1 dose.

Varicella vaccines (WHO position paper)

In immunocompromised persons, including patients with advanced HIV infection, varicella vaccination is currently contraindicated for fear of disseminated vaccine induced disease.

Varicella vaccines (WHO position paper)

Contraindications for varicella vaccination include a history of anaphylactic reactions to any component of the vaccine (including neomycin), pregnancy (due to theoretical risk to the fetus; pregnancy should be avoided for 4 weeks following vaccination), ongoing severe illness, and advanced immune disorders of any type.

Except for patients with acute lymphatic leukaemia in stable remission, ongoing treatment with systemic steroids (for adults >20 mg/day, for children >1mg/kg/day) is considered a contraindication for varicella vaccination. A history of congenital immune disorders in close family members is a relative contraindication.

Varicella vaccines (WHO position paper)

Due to the theoretical risk of Reye syndrome, the use of salicylates is discouraged for 6 weeks following varicella vaccination.
Varicella vaccines (WHO position paper)

The likelihood that every child will contract varicella, combined with a socioeconomic structure that implies high indirect costs for each case, make varicella relatively important in industrialized countries with temperate climates. Routine childhood vaccination against this disease is estimated to be cost-effective in such areas.

In most developing countries other new vaccines, including hepatitis B, rotavirus, as well as conjugated Haemophilus influenzae type b and pneumococcal vaccines, have the potential for a much greater public health impact (than varicella vaccine), and should therefore be given priority over varicella vaccines. Hence, at the present time WHO does not recommend the inclusion of varicella vaccination into the routine immunization programmes of developing countries.

Varicella vaccines (WHO position paper)

Routine childhood varicella immunization programmes should emphasize high, sustained coverage.

Varicella vaccines (WHO position paper)

Recommendations on possible use of (varicella) vaccine for persons in certain states of immunodeficiency are beyond the scope of this article. Advice is provided by several expert panels such as the Advisory Committee on Immunization Practices (ACIP) in the United States.

Temperature sensitivity of vaccines

The lyophilized form (of varicella vaccine) can be stored at refrigerator temperature for 1.5 years or more, but manufacturers suggest it is better stored frozen. It should not be refrozen.

HIV/AIDS and immunosuppression

Varicella vaccines (WHO position paper)

In immunocompromised persons, including patients with advanced HIV infection, varicella vaccination is currently contraindicated for fear of disseminated vaccine induced disease.

Immunization Coverage

Varicella vaccines (WHO position paper)

Routine childhood varicella immunization programmes should emphasize high, sustained coverage.
New Vaccines

Varicella vaccines (WHO position paper)

Routine childhood immunization against varicella may be considered in countries where this disease is a relatively important public health and socioeconomic problem, where the vaccine is affordable, and where high (85%-90%) and sustained vaccine coverage can be achieved. (Childhood immunization with lower coverage could theoretically shift the epidemiology of the disease and increase the number of severe cases in older children and adults.)

Varicella vaccines (WHO position paper)

The likelihood that every child will contract varicella, combined with a socioeconomic structure that implies high indirect costs for each case, make varicella relatively important in industrialized countries with temperate climates. Routine childhood vaccination against this disease is estimated to be cost-effective in such areas.

In most developing countries other new vaccines, including hepatitis B, rotavirus, as well as conjugated Haemophilus influenzae type b and pneumococcal vaccines, have the potential for a much greater public health impact (than varicella vaccine), and should therefore be given priority over varicella vaccines. Hence, at the present time WHO does not recommend the inclusion of varicella vaccination into the routine immunization programmes of developing countries.

Policy

Varicella vaccines (WHO position paper)

Routine childhood immunization against varicella may be considered in countries where this disease is a relatively important public health and socioeconomic problem, where the vaccine is affordable, and where high (85%-90%) and sustained vaccine coverage can be achieved. (Childhood immunization with lower coverage could theoretically shift the epidemiology of the disease and increase the number of severe cases in older children and adults.)

Varicella vaccines (WHO position paper)

(Varicella) vaccine may be offered in any country to individual adolescents and adults without a history of varicella, in particular to those at increased risk of contracting or spreading the infection. This use in adolescents and adults entails no risk of an epidemiological shift, as childhood exposure to VZV remains unaffected.

Varicella vaccines (WHO position paper)

In immunocompromised persons, including patients with advanced HIV infection, varicella vaccination is currently contraindicated for fear of disseminated vaccine induced disease.
Contraindications for varicella vaccination include a history of anaphylactic reactions to any component of the vaccine (including neomycin), pregnancy (due to theoretical risk to the fetus; pregnancy should be avoided for 4 weeks following vaccination), ongoing severe illness, and advanced immune disorders of any type.

Except for patients with acute lymphatic leukaemia in stable remission, ongoing treatment with systemic steroids (for adults >20 mg/day, for children >1mg/kg/day) is considered a contraindication for varicella vaccination. A history of congenital immune disorders in close family members is a relative contraindication.

Due to the theoretical risk of Reye syndrome, the use of salicylates is discouraged for 6 weeks following varicella vaccination.

The likelihood that every child will contract varicella, combined with a socioeconomic structure that implies high indirect costs for each case, make varicella relatively important in industrialized countries with temperate climates. Routine childhood vaccination against this disease is estimated to be cost-effective in such areas.

In most developing countries other new vaccines, including hepatitis B, rotavirus, as well as conjugated Haemophilus influenzae type b and pneumococcal vaccines, have the potential for a much greater public health impact (than varicella vaccine), and should therefore be given priority over varicella vaccines. Hence, at the present time WHO does not recommend the inclusion of varicella vaccination into the routine immunization programmes of developing countries.

Routine childhood varicella immunization programmes should emphasize high, sustained coverage.

The lyophilized form (of varicella vaccine) can be stored at refrigerator temperature for 1.5 years or more, but manufacturers suggest it is better stored frozen. It should not be refrozen.
Pregnant Women

Varicella vaccines (WHO position paper)

Contraindications for varicella vaccination include a history of anaphylactic reactions to any component of the vaccine (including neomycin), pregnancy (due to theoretical risk to the fetus; pregnancy should be avoided for 4 weeks following vaccination), ongoing severe illness, and advanced immune disorders of any type.

Except for patients with acute lymphatic leukaemia in stable remission, ongoing treatment with systemic steroids (for adults >20 mg/day, for children >1mg/kg/day) is considered a contraindication for varicella vaccination. A history of congenital immune disorders in close family members is a relative contraindication.

Schedule

Varicella vaccines (WHO position paper)

(Varicella) vaccine may be offered in any country to individual adolescents and adults without a history of varicella, in particular to those at increased risk of contracting or spreading the infection. This use in adolescents and adults entails no risk of an epidemiological shift, as childhood exposure to VZV remains unaffected.

Varicella vaccines (WHO position paper)

From a logistic as well as an epidemiological point of view, the optimal age for varicella vaccination is 12-24 months.

In Japan and several other countries 1 dose of the (varicella) vaccine is considered sufficient, regardless of age. In the United States, 2 doses, 4-8 weeks apart, are recommended for adolescents and adults, in whom 78% were found to have seroconverted after the first, and 99% after the second dose of the vaccine. Children below 13 years receive only 1 dose.

Vaccine Administration

Varicella vaccines (WHO position paper)

When given at separate sites and with separate syringes, simultaneous vaccination of varicella with other vaccines is as safe and immunogenic as when the vaccines are given at intervals of several weeks.

Varicella vaccines (WHO position paper)

Due to the theoretical risk of Reye syndrome, the use of salicylates is discouraged for 6 weeks following varicella vaccination.
Vaccine Handling

Temperature sensitivity of vaccines

The lyophilized form (of varicella vaccine) can be stored at refrigerator temperature for 1.5 years or more, but manufacturers suggest it is better stored frozen. It should not be refrozen.